# Exact Sciences (Abbott)

Source: https://onco.cc/companies/exact-sciences/  
OnCo record `exact-sciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Exact Sciences makes Cologuard and Oncotype DX and is launching Cancerguard MCED and Oncodetect MRD; Abbott completed its purchase of the company on 23 March 2026.

## Summary

Exact Sciences, based in Madison, Wisconsin, makes Cologuard and Oncotype DX and is launching the Cancerguard multi-cancer early detection test and the Oncodetect residual disease test. Abbott completed its purchase of the company, agreed at about 21 billion dollars, on 23 March 2026. Its products span Cologuard Plus for stool-based colorectal screening, Oncotype DX for breast cancer recurrence risk, Oncodetect for MRD and Cancerguard, offered as a laboratory-developed test from 2025. OnCo links it to colorectal and HR-positive breast cancer, to MRD testing and multi-cancer early detection, to the early detection roadmap from organ screening to blood tests, and to Abbott Laboratories. Whether the Abbott deal turns a screening franchise into a broader diagnostics platform is the open question. Each product has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Madison, WI
- Type: diagnostics
- Website: https://www.exactsciences.com

## Sources

- Official website: https://www.exactsciences.com
- Abbott completes acquisition of Exact Sciences (23 March 2026): https://abbott.mediaroom.com/2026-03-23-Abbott-completes-acquisition-of-Exact-Sciences

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- drugs: [Cancerguard](https://onco.cc/drugs/cancerguard/), [CancerSEEK](https://onco.cc/drugs/cancerseek/), [Cologuard](https://onco.cc/drugs/cologuard/), [Cologuard Plus](https://onco.cc/drugs/cologuard-plus/), [Oncodetect](https://onco.cc/drugs/oncodetect/), [Oncotype DX](https://onco.cc/drugs/oncotype-dx/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- key papers: [Multitarget stool DNA testing for colorectal-cancer screening](https://onco.cc/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/), [Performance of a multi-biomarker class, multi-cancer early detection (MCED) blood test in a prospectively collected cohort](https://onco.cc/key-papers/paper-cancerguard-mp-classifier-cebp-2026/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [Multitarget stool RNA test (ColoSense)](https://onco.cc/technologies/multitarget-stool-rna-test/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/), [Early detection roadmap: organ screening → blood tests for many cancers](https://onco.cc/roadmaps/early-detection-roadmap/)
- bottlenecks: [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)
- trials: [Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct06850623/), [ASCEND (CancerSEEK case-control collection)](https://onco.cc/trials/ascend-cancerseek/), [BLUE-C](https://onco.cc/trials/blue-c/), [DeeP-C](https://onco.cc/trials/deep-c/), [Falcon Registry (Exact Sciences multi-cancer test real-world evidence)](https://onco.cc/trials/falcon-registry/), [REGENERATE (genetic and multi-cancer test education for people at pancreatic cancer risk)](https://onco.cc/trials/regenerate-pancreatic-genetics-mced/)
- companies: [Abbott Laboratories](https://onco.cc/companies/abbott/)

---
JSON: https://onco.cc/api/v1/entities/exact-sciences.json